Urology Times staff

A focal point of the discussion was the ARANOTE trial, which examined darolutamide plus ADT versus ADT alone in men with metastatic hormone-sensitive prostate cancer who had not received chemotherapy

The discussion opened with how clinicians interpret the term intermediate risk in NMIBC—a category that can encompass multifocal low-grade Ta lesions, solitary tumors larger than 3 cm, or recurrent low-grade disease within 1 year.

The group agreed that the intermediate-risk space is where decision-making is most nuanced.

In this episode, Gregory E. Tasian, MD, MSc, MSCE, Jonathan S. Ellison, MD, and patient partner Annabelle Pleskoff reflect on the origins, design, and key findings of the PKIDS trial.

The logistics of delivery of treatment—such as patient premedication, bladder drainage, and instillation technique—were discussed.

Panelists discussed how they might incorporate chemoablation into clinical workflows.

Several clinicians observed that patients often fail to understand the distinction between NMIBC and muscle-invasive disease, complicating counseling and referrals.

There was a consensus that soon, combinations like darolutamide plus androgen deprivation are becoming standard options for certain patient populations.

A key theme throughout the discussion was the importance of personalized treatment strategies based on patient-specific factors.

Catch up on exclusive videos you may have missed from the first half of the year.

The conversation touched on risk stratification, which plays a central role in deciding among surgical options.

A major challenge addressed in the Clinical Forum was managing BCG shortages and the implications for patient care.

This Clinical Forum event provided a comprehensive overview of the current landscape in treating NMIBC.

The Clinical Forum underscored the importance of clinical trials and multidisciplinary collaboration in advancing bladder cancer care.

"When we select abiraterone for our patients with mHSPC, there's a choice between generic and branded options," says Paul C. Dato MD.

A recent Urology Times Clinical Forum provided an in-depth overview of current and emerging strategies for managing NMIBC.

A pair of roundtable discussions encompassed a range of topics related to UTUC, including clinical guidelines, treatment considerations, and patient cases.

Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.

Three recent expert-led Clinical Forums explored current challenges and advancements in the management of non–muscle invasive bladder cancer.

In 2 recent case-based roundtable discussions, experts tackled diagnosis and treatment strategy for upper tract urothelial carcinoma.

Hear insights from experts on key trial data presented at ASCO GU 2025.

Two recent roundtable discussions focused on the challenges and evolving treatment strategies in upper tract urothelial carcinoma.

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

Two case-based roundtable discussions recently covered the advancing of care for patients with low-grade upper tract urothelial carcinoma.

"Over a third of Americans actually use some kind of what we term complementary or alternative medicine approach," says Raevti Bole, MD.

“We really need to do a better job of destigmatizing these conversations so guys are comfortable asking their providers [about sensitive health issues],” says Justin Dubin, MD.

“Now for muscle-invasive [disease], how I counsel patients on surgery when they're a man vs a woman is almost completely different, because their anatomy is very different,” says Ava Saidian, MD.

"We found actually that patients who underpredict their curve during the initial visit, prior to having a formal measurement of their penile curvature, actually ended up having a higher satisfaction following treatment," says Jake Miller, MD.

Michael Jenson, PA-C, gives an overview of the Surgical Impotence Management Strategy program at Minnesota Urology.